Avecho Biotechnology Limited (ASX:AVE)

1.4¢

right-arrow Created with Sketch. -0.001 (-6.67%)
MCAP $27.56M
Last trade 16.10pm 24/01/2022 20mins delayed

Latest Announcements

10/01/2022AVEAvecho Biotechnology Limited
10/01/2022AVEAvecho Biotechnology Limited
20/12/2021 Price SensitivePSAVEAvecho Biotechnology Limited
08/12/2021 Price SensitivePSAVEAvecho Biotechnology Limited
29/10/2021 Price SensitivePSAVEAvecho Biotechnology Limited
21/10/2021 Price SensitivePSAVEAvecho Biotechnology Limited
04/10/2021 Price SensitivePSAVEAvecho Biotechnology Limited
15/09/2021 Price SensitivePSAVEAvecho Biotechnology Limited

Company Overview

Avecho Biotechnology Limited is an Australia-based company that develops and commercializes human and animal health products using its drug delivery system Tocopherol Phosphate Mixture (TPM). The Company's products pipeline includes Weaner Pig Starter TPM premix, Poultry TPM, Dairy TPM, and Veterinary Applications. The Company's segments include Production and Personal Care and Human Health. The Production and Personal Care segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches. The Human Health segment focuses on the development of patches, including TPM/Oxymorphone, TPM/enhanced, and TPM/Oxycodone. Its TPM products are commercialized under license Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.

AVE in the news

Avecho Biotechnology (AVE) entered a product licence and supply agreement with vitamin…
Avecho Biotechnology (AVE) releases results for its Phase I PK study characterising…
Avecho Biotechnology (AVE) begins dosing volunteers for its clinical trial measuring CBD…
Avecho (AVE) kicks off enrolment for its phase one human clinical trial…

Search Previous Announcements